{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:55:44Z","timestamp":1768899344993,"version":"3.49.0"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["2016GXNSFDA380029"],"award-info":[{"award-number":["2016GXNSFDA380029"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["2018GXNSFBA281026"],"award-info":[{"award-number":["2018GXNSFBA281026"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are over a 100 driver gene mutations in patients with diffuse large B\u2010cell lymphoma (DLBCL), but their clinical significance remains unclear. Here, we first analyzed the DLBCL dataset from the UK\u2010based Haematological Malignancy Research Network. Patients were divided into high\u2010 and low\u2010risk groups based on whether lymphoma progressed within 24\u00a0months. Genes showing significantly different frequencies between groups were selected. Survival data for patients with the selected mutant genes were analyzed. The results were validated using two other large databases to evaluate the relationship between the selected mutant genes and prognosis. The mutation frequencies of 11 genes (<jats:italic>MYD88<\/jats:italic>[L265P], <jats:italic>SGK1<\/jats:italic>, <jats:italic>MPEG1<\/jats:italic>, <jats:italic>TP53<\/jats:italic>, <jats:italic>SPEN<\/jats:italic>, <jats:italic>NOTCH1<\/jats:italic>, <jats:italic>ETV6<\/jats:italic>, <jats:italic>TNFRSF14<\/jats:italic>, <jats:italic>MGA<\/jats:italic>, <jats:italic>CIITA<\/jats:italic>, and <jats:italic>PIM1<\/jats:italic>) significantly differed between the high\u2010 and low\u2010risk groups. The relationships between these mutant genes and patient survival were analyzed. Patients who harbored <jats:italic>SGK1<\/jats:italic> (serum and glucocorticoid\u2010inducible kinase 1) mutations exhibited the best prognosis. Most patients with SGK1 mutation are germinal center B\u2010cell (GCB) subtype. Among patients with GCB DLBCL, those harboring <jats:italic>SGK1<\/jats:italic> mutations exhibited better prognosis than those without <jats:italic>SGK1<\/jats:italic> mutations. Most <jats:italic>SGK1<\/jats:italic> mutations were single\u2010base substitutions, primarily scattered throughout the catalytic domain\u2010encoding region. Multiple <jats:italic>SGK1<\/jats:italic> mutations were identified in a single patient. Thus, <jats:italic>SGK1<\/jats:italic> mutations are a marker of good prognosis for DLBCL and occur predominantly in the GCB subtype of DLBCL. <jats:italic>SGK1<\/jats:italic> mutation status can further stratify patients with GCB DLBCL into different prognostic subgroups.<\/jats:p>","DOI":"10.1002\/cam4.4550","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T04:03:30Z","timestamp":1643774610000},"page":"1281-1291","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["<i>SGK1<\/i> mutation status can further stratify patients with germinal center B\u2010cell\u2010like diffuse large B\u2010cell lymphoma into different prognostic subgroups"],"prefix":"10.1002","volume":"11","author":[{"given":"Baoping","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Chemotherapy Guangxi Medical University Affiliated Tumor Hospital  Nanning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujie","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy Guangxi Medical University Affiliated Tumor Hospital  Nanning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy Guangxi Medical University Affiliated Tumor Hospital  Nanning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0408-6684","authenticated-orcid":false,"given":"Chengcheng","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy Guangxi Medical University Affiliated Tumor Hospital  Nanning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-5692","authenticated-orcid":false,"given":"Hong","family":"Cen","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy Guangxi Medical University Affiliated Tumor Hospital  Nanning China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0016-8"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003535"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.214122"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106426"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.027"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1101\/gr.239244.118"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0430-y"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph13110413"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.07.009"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/381751a0"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-020711-075032"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.09.001"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.05.011"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1401"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2822"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20082202"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010432"},{"issue":"2","key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1158\/0008-5472.457.65.2","article-title":"Antiapoptotic effect of serum and glucocorticoid\u2010inducible protein kinase is mediated by novel mechanism activating I\u03baB kinase","volume":"65","author":"Zhang L","year":"2005","journal-title":"Cancer Res"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2010.05.016"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25850"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-17-0146"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000354486"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22500"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.293"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2105"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2018.05.001"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000447885"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.4161\/15384047.2014.986982"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33008-9"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00999"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4550","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4550","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T12:16:21Z","timestamp":1693138581000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1002\/cam4.4550"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4550","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"2021-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}